Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Stuart A. Arbuckle sold 4,250 shares of the stock in a transaction on Thursday, January 11th. The shares were sold at an average price of $159.00, for a total value of $675,750.00. Following the completion of the transaction, the executive vice president now directly owns 46,202 shares in the company, valued at approximately $7,346,118. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Shares of Vertex Pharmaceuticals Incorporated (VRTX) traded down $0.47 during trading on Friday, reaching $157.93. The company had a trading volume of 1,561,110 shares, compared to its average volume of 1,530,000. The firm has a market cap of $39,940.00, a P/E ratio of 202.47, a PEG ratio of 1.87 and a beta of 1.58. Vertex Pharmaceuticals Incorporated has a twelve month low of $79.78 and a twelve month high of $167.85. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.28 and a quick ratio of 3.14.
Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Wednesday, October 25th. The pharmaceutical company reported $0.53 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.04 by $0.49. The business had revenue of $578.20 million for the quarter, compared to the consensus estimate of $522.07 million. Vertex Pharmaceuticals had a return on equity of 9.23% and a net margin of 8.53%. The firm’s revenue was up 39.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.16 EPS. equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 0.76 EPS for the current fiscal year.
A number of institutional investors have recently modified their holdings of VRTX. Smithfield Trust Co. acquired a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter valued at about $135,000. Northwestern Mutual Wealth Management Co. raised its stake in shares of Vertex Pharmaceuticals by 15.4% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 988 shares of the pharmaceutical company’s stock valued at $127,000 after purchasing an additional 132 shares during the period. FNY Managed Accounts LLC acquired a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter valued at about $162,000. Fuller & Thaler Asset Management Inc. acquired a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter valued at about $198,000. Finally, Intact Investment Management Inc. acquired a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter valued at about $213,000. 93.09% of the stock is currently owned by institutional investors and hedge funds.
VRTX has been the topic of a number of analyst reports. DA Davidson initiated coverage on Vertex Pharmaceuticals in a research note on Friday, September 29th. They issued a “buy” rating and a $200.00 price target on the stock. BTIG Research initiated coverage on Vertex Pharmaceuticals in a research note on Friday, September 29th. They issued a “buy” rating and a $200.00 price target on the stock. BMO Capital Markets reissued a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Wednesday, September 27th. Needham & Company LLC reissued a “buy” rating and issued a $195.00 price target on shares of Vertex Pharmaceuticals in a research note on Sunday, September 17th. Finally, Maxim Group reissued a “buy” rating and issued a $195.00 price target on shares of Vertex Pharmaceuticals in a research note on Thursday, October 26th. One analyst has rated the stock with a sell rating, three have given a hold rating, twenty-five have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $175.89.
WARNING: “Vertex Pharmaceuticals Incorporated (VRTX) EVP Sells $675,750.00 in Stock” was posted by Transcript Daily and is the property of of Transcript Daily. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://transcriptdaily.com/2018/01/13/vertex-pharmaceuticals-incorporated-vrtx-evp-sells-675750-00-in-stock.html.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.